Youjin Oh

Internal Medicine

1901 W Harrison St
Chicago, IL 60612

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

CLO26-107: A Meta-Analysis and Network Meta-Analysis for Overall Survival of Pembrolizumab Monotherapy Versus Combined With Chemotherapy as First-Line Therapy in No EGFR/ALK-Mutation Advanced or Metastatic Non-Small-Cell Lung Cancer.

CLO26-107: A Meta-Analysis and Network Meta-Analysis for Overall Survival of Pembrolizumab Monotherapy Versus Combined With Chemotherapy as First-Line Therapy in No EGFR/ALK-Mutation Advanced or Metastatic Non-Small-Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 30, 2026

CLO26-102: Progression-Free Survival of Pembrolizumab Monotherapy Versus Combination Therapy With Chemotherapy as First-Line Treatment in Advanced or Metastatic Non-Small-Cell Lung Cancer Without EGFR/ALK Mutations: A Systematic Review and Robust Meta-Analysis.

CLO26-102: Progression-Free Survival of Pembrolizumab Monotherapy Versus Combination Therapy With Chemotherapy as First-Line Treatment in Advanced or Metastatic Non-Small-Cell Lung Cancer Without EGFR/ALK Mutations: A Systematic Review and Robust Meta-Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

CLO26-107: A Meta-Analysis and Network Meta-Analysis for Overall Survival of Pembrolizumab Monotherapy Versus Combined With Chemotherapy as First-Line Therapy in No EGFR/ALK-Mutation Advanced or Metastatic Non-Small-Cell Lung Cancer.

CLO26-107: A Meta-Analysis and Network Meta-Analysis for Overall Survival of Pembrolizumab Monotherapy Versus Combined With Chemotherapy as First-Line Therapy in No EGFR/ALK-Mutation Advanced or Metastatic Non-Small-Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

CLO26-102: Progression-Free Survival of Pembrolizumab Monotherapy Versus Combination Therapy With Chemotherapy as First-Line Treatment in Advanced or Metastatic Non-Small-Cell Lung Cancer Without EGFR/ALK Mutations: A Systematic Review and Robust Meta-Analysis.

CLO26-102: Progression-Free Survival of Pembrolizumab Monotherapy Versus Combination Therapy With Chemotherapy as First-Line Treatment in Advanced or Metastatic Non-Small-Cell Lung Cancer Without EGFR/ALK Mutations: A Systematic Review and Robust Meta-Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib.

Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib.

Journal: Oncotarget

Published: May 29, 2025

Radiomics Models to Predict Tumor Response and Pneumonitis in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.

Radiomics Models to Predict Tumor Response and Pneumonitis in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.

Journal: Journal of clinical medicine

Published: February 13, 2025

Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors.

Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors.

Journal: Cancer medicine

Published: June 29, 2024

Trends, Sociodemographic and Hospital-Level Factors Associated with Palliative Care Utilization Among Metastatic Prostate Cancer Patients.

Trends, Sociodemographic and Hospital-Level Factors Associated with Palliative Care Utilization Among Metastatic Prostate Cancer Patients.

Journal: The American journal of hospice & palliative care

Published: May 23, 2024

Current Status of Anti-Reflux Surgery as a Treatment for GERD.

Current Status of Anti-Reflux Surgery as a Treatment for GERD.

Journal: Medicina (Kaunas, Lithuania)

Published: February 24, 2024

Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.

Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.

Journal: Thoracic cancer

Published: January 07, 2024

Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.

Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.

Journal: Clinical lung cancer

Published: October 22, 2023

Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with PTEN mutation: a case report and literature review.

Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with PTEN mutation: a case report and literature review.

Journal: Frontiers in endocrinology

Published: September 29, 2023

Showing 1-12 of 16

Last Updated: 09/26/2026